Caffeine increases the antitumor effect of cisplatin in human hepatocellular carcinoma cells

Biological and Pharmaceutical Bulletin

Volumn 35, Issue 3, 2012, Pages 400-407

  Kawano, Yohei ^a   Nagata, Masashi ^b   Kohno, Takafumi ^a   Ichimiya, Akihiro ^a   Iwakiri, Tomomi ^a   Okumura, Manabu ^a   Arimori, Kazuhiko ^a  

^a UNIVERSITY OF MIYAZAKI HOSPITAL   (Japan)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

Caffeine; Cisplatin; Combination chemotherapy; Hepatocellular carcinoma; Pharmacodynamics

Indexed keywords

CAFFEINE; CISPLATIN; FLUORESCEIN ISOTHIOCYANATE; LIPOCORTIN 5; PROPIDIUM IODIDE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BINDING KINETICS; CANCER CELL CULTURE; CELL ASSAY; CELL COUNT; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG POTENTIATION; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER CELL CARCINOMA;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CAFFEINE; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; CISPLATIN; DRUG THERAPY, COMBINATION; HEPATOCYTES; HUMANS;

EID: 84857822364     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.35.400     Document Type: Article

References (40)

1. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology, 132, 2557-2576 (2007).
2. Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol., 2, 533-543 (2001).
3. Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology, 127 (Suppl 1), S35-S50 (2004).
4. Kato Y, Nakata K, Omagari K, Furukawa R, Kusumoto Y, Mori I, Tajima H, Tanioka H, Yano M, Nagataki S. Risk of hepatocellular carcinoma in patients with cirrhosis in Japan. Analysis of infectious hepatitis viruses. Cancer, 74, 2234-2238 (1994).
5. Ebara M, Ohto M, Sugiura N, Kita K, Yoshikawa M, Okuda K, Kondo F, Kondo Y. Percutaneous ethanol injection for the treatment of small hepatocellular carcinoma. Study of 95 patients. J. Gastroenterol. Hepatol., 5, 616-626 (1990).
6. Matsui O, Kadoya M, Yoshikawa J, Gabata T, Arai K, Demachi H, Miyayama S, Takashima T, Unoura M, Kogayashi K. Small hepatocellular carcinoma: treatment with subsegmental transcatheter arterial embolization. Radiology, 188, 79-83 (1993).
7. Seki T, Wakabayashi M, Nakagawa T, Itho T, Shiro T, Kunieda K, Sato M, Uchiyama S, Inoue K. Ultrasonically guided percutaneous microwave coagulation therapy for small hepatocellular carcinoma. Cancer, 74, 817-825 (1994).
8. Livraghi T, Goldberg SN, Lazzaroni S, Meloni F, Solbiati L, Gazelle GS. Small hepatocellular carcinoma: treatment with radiofrequency ablation versus ethanol injection. Radiology, 210, 655-661 (1999).
9. Okuda K, Ohtsuki T, Obata H, Tomimatsu M, Okazaki N, Hasegawa H, Nakajima Y, Ohnishi K. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer, 56, 918-928 (1985).
10. Sciarrino E, Simonetti RG, Le Moli S, Pagliaro L. Adriamycin treatment for hepatocellular carcinoma. Experience with 109 patients. Cancer, 56, 2751-2755 (1985).
11. Okada S, Okazaki N, Nose H, Shimada Y, Yoshimori M, Aoki K. A phase 2 study of cisplatin in patients with hepatocellular carcinoma. Oncology, 50, 22-26 (1993).
12. Lee J, Park JO, Kim WS, Park SH, Park KW, Choi MS, Lee JH, Koh KC, Paik SW, Yoo BC, Joh J, Kim K, Jung CW, Park YS, Im YH, Kang WK, Lee MH, Park K. Phase II study of doxorubicin and cisplatin in patients with metastatic hepatocellular carcinoma. Cancer Chemother. Pharmacol., 54, 385-390 (2004).
13. Parikh PM, Fuloria J, Babu G, Doval DC, Awasthy BS, Pai VR, Prabhakaran PS, Benson AB. A phase II study of gemcitabine and cisplatin in patients with advanced hepatocellular carcinoma. Trop. Gastroenterol., 26, 115-118 (2005).
14. Lee JO, Lee KW, Oh DY, Kim JH, Im SA, Kim TY, Bang YJ. Combination chemotherapy with capecitabine and cisplatin for patients with metastatic hepatocellular carcinoma. Ann. Oncol., 20, 1402-1407 (2009).
15. Ikeda M, Okusaka T, Ueno H, Takezako Y, Morizane C. A phase II trial of continuous infusion of 5-fluorouracil, mitoxantrone, and cisplatin for metastatic hepatocellular carcinoma. Cancer, 103, 756-762 (2005).
16. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med., 359, 378-390 (2008).
17. Tsuchiya H, Abdel-Wanis ME, Sakurakichi K, Yamashiro T, Tomita K. Osteosarcoma around the knee. Intraepiphyseal excision and biological reconstruction with distraction osteogenesis. J. Bone Joint Surg. Br., 84, 1162-1166 (2002).
18. Tsuchiya H, Tomita K, Mori Y, Asada N, Yamamoto N. Marginal excision for osteosarcoma with caffeine assisted chemotherapy. Clin. Orthop. Relat. Res., 358, 27-35 (1999).
19. Tsuchiya H, Tomita K, Yasutake H, Takagi Y, Katsuo S, Tokuumi Y, Sugihara M. Intraarterial Cisplatin and caffeine with/without Doxorubicin for musculoskeletal high-grade spindle-cell sarcoma. Oncol. Rep., 1, 27-36 (1994).
20. Kanazawa Y, Tsuchiya H, Nonomura A, Takazawa K, Yamamoto N, Tomita K. Intentional marginal excision of osteosarcoma of the proximal fibula to preserve limb function. J. Orthop. Sci., 8, 757-761 (2003).
21. Hayashi M, Tsuchiya H, Yamamoto N, Karita M, Shirai T, Nishida H, Takeuchi A, Tomita K. Caffeine-potentiated chemotherapy for metastatic carcinoma and lymphoma of bone and soft tissue. Anticancer Res., 25 (3c), 2399-2405 (2005).
22. Takeuchi A, Tsuchiya H, Yamamoto N, Hayashi K, Yamauchi K, Kawahara M, Miyamoto K, Tomita K. Caffeine-potentiated chemotherapy for patients with high-grade soft tissue sarcoma: long-term clinical outcome. Anticancer Res., 27 (5B), 3489-3495 (2007).
23. Gururajanna B, Al-Katib AA, Li YW, Aranha O, Vaitkevicius VK, Sarkar FH. Molecular effects of taxol and caffeine on pancreatic cancer cells. Int. J. Mol. Med., 4, 501-507 (1999).
24. Takahashi M, Yanoma S, Yamamoto Y, Rino Y, Amano T, Imada T. Combined effect of CDDP and caffeine against human gastric cell line in vivo. Anticancer Res., 18 (6A), 4399-4401 (1998).
25. Ohsaki Y, Ishida S, Fujikane T, Akiba Y, Osanai S, Onodera S. Combination effect of caffeine and cisplatin on a cisplatin resistant human lung cancer cell line. Gan To Kagaku Ryoho, 17, 1339-1343 (1990).
26. Yamaoka K, Tanigawara Y, Nakagawa T, Uno T. A pharmacokinetic analysis program (multi) for microcomputer. J. Pharmacobiodyn., 4, 879-885 (1981).
27. He Z, Ma WY, Hashimoto T, Bode AM, Yang CS, Dong Z. Induction of apoptosis by caffeine is mediated by the p53, Bax, and caspase 3 pathways. Cancer Res., 63, 4396-4401 (2003).
28. Ito K, Nakazato T, Miyakawa Y, Yamato K, Ikeda Y, Kizaki M. Caffeine induces G2/M arrest and apoptosis via a novel p53-dependent pathway in NB4 promyelocytic leukemia cells. J. Cell. Physiol., 196, 276-283 (2003).
29. Zhu AX. Systemic therapy of advanced hepatocellular carcinoma: how hopeful should we be? Oncologist, 11, 790-800 (2006).
30. Vexler AM, Mou X, Gabizon AA, Gorodetsky R. Reduction of the systemic toxicity of cisplatin by intra-arterial hepatic route administration for liver malignancies. Int. J. Cancer, 60, 611-615 (1995).
31. Damia G, Filiberti L, Vikhanskaya F, Carrassa L, Taya Y, D'incalci M, Broggini M. Cisplatinum and taxol induce different patterns of p53 phosphorylation. Neoplasia, 3, 10-16 (2001).
32. Zhao H, Piwnica-Worms H. ATR-mediated checkpoint pathways regulate phosphorylation and activation of human Chk1. Mol. Cell. Biol., 21, 4129-4139 (2001).
33. Sarkaria JN, Busby EC, Tibbetts RS, Roos P, Taya Y, Karnitz LM, Abraham RT. Inhibition of ATM and ATR kinase activities by the radiosensitizing agent, caffeine. Cancer Res., 59, 4375-4382 (1999).
34. Hashimoto T, He Z, Ma WY, Schmid PC, Bode AM, Yang CS, Dong Z. Caffeine inhibits cell proliferation by G0/G1 phase arrest in JB6 cells. Cancer Res., 64, 3344-3349 (2004).
35. Foukas LC, Daniele N, Ktori C, Anderson KE, Jensen J, Shepherd PR. Direct effects of caffeine and theophylline on p110 delta and other phosphoinositide 3-kinases. Differential effects on lipid kinase and protein kinase activities. J. Biol. Chem., 277, 37124-37130 (2002).
36. Jha MN, Bamburg JR, Bernstein BW, Bedford JS. Caffeine eliminates gamma-ray-induced G2-phase delay in human tumor cells but not in normal cells. Radiat. Res., 157, 26-31 (2002).
37. Hayashi K, Tsuchiya H, Yamamoto N, Shirai T, Yamauchi K, Takeuchi A, Kawahara M, Miyamoto K, Tomita K. Impact of se rum caffeine monitoring on adverse effects and chemotherapeutic responses to caffeine-potentiated chemotherapy for osteosarcoma. J. Orthop. Sci., 14, 253-258 (2009).
38. Juliano LM, Griffiths RR. A critical review of caffeine withdrawal: empirical validation of symptoms and signs, incidence, severity, and associated features. Psychopharmacology (Berl.), 176, 1-29 (2004).
39. Leson CL, McGuigan MA, Bryson SM. Caffeine overdose in an adolescent male. J. Toxicol. Clin. Toxicol., 26, 407-415 (1988).
40. Dalvi RR. Acute and chronic toxicity of caffeine: a review. Vet. Hum. Toxicol., 28, 144-150 (1986).